Inspira delivered major milestones throughout and following the six months ended June 30, 2025, including the receipt of $49.5 million in binding purchase orders, clinical validation in leading hospitals, 97.35% accuracy for its HYLA blood sensor, and strategic patent protection, underscoring accelerating commercial momentum.RA'ANANA, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (“Inspira” or the “Company”), a pioneer in innovative life-support and di ...

Core Insights - Inspira Technologies has expanded the clinical use of its INSPIRA™ ART100 system to lung transplantation procedures at a top U.S. hospital, indicating strong validation of the system's performance and clinical value [1][2] - The expansion reflects growing confidence from leading hospitals in Inspira's technology and highlights the ART100's potential as a reliable platform for advanced respiratory support [2][3] - The company has recently secured multi-million dollar binding government orders for ART100 systems, showcasing its increasing global footprint and commercial momentum [3] Company Overview - Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions [4] - The INSPIRA™ ART100 system is FDA-cleared for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., with plans for a next-generation system, the INSPIRA ART500, designed for awake patients [4] - The company is advancing its proprietary blood sensor platform, HYLA™, and is strategically streamlining operations to align with long-term industry trends such as consolidation and potential strategic partnerships [4]

RA'ANANA, Israel, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life- support and diagnostic technologies, has received U.S. Patent approval for low flow rates extracorporeal oxygenation system and methods of use. This patent represents the core technology of the ART500 device, a key asset in the Company's strategy to penetrate the $20 billion estimated market for advanced respiratory supp ...

Core Insights - Inspira Technologies is scaling up production capabilities for its FDA-cleared INSPIRA™ ART100 system in response to anticipated demand from a European governmental authority, with advanced-stage procurement negotiations underway [1][2][3] - The ART100 system is already in clinical use in the U.S. and is recognized as a reliable device for critical care and emergency preparedness [2][3] - The company aims to fast-track revenue generation from the ART100 system while continuing to develop next-generation platforms, including the ART500 and HYLA™ blood sensor [3][4] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with the ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [5] - The ART500 is a next-generation system designed to provide oxygenation while patients remain awake and spontaneously breathing, and the HYLA™ platform offers continuous, non-invasive blood monitoring [5] - The company is positioned as an attractive platform within the critical care and MedTech landscape, reflecting broader industry trends such as consolidation and cross-sector collaboration [5]

Core Insights - Inspira Technologies has scaled up production capabilities for its FDA-cleared INSPIRA ART100 system in anticipation of demand from a European governmental authority, with advanced-stage procurement negotiations ongoing [1][2][3] - The ART100 system is already in clinical use in the U.S. and is recognized as a reliable device for critical care and emergency preparedness [2][3] - The company aims to fast-track revenue generation from the ART100 system while continuing to develop next-generation platforms, including the ART500 and HYLA blood sensor [3][4] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with the ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [5] - The ART500 is a next-generation system designed to provide oxygenation while patients remain awake and spontaneously breathing, and the HYLA platform offers continuous, non-invasive blood monitoring [5] - The company is positioned as an attractive platform within the critical care and MedTech landscape, reflecting broader industry trends such as consolidation and potential strategic partnerships [5]